Benefit of palliative chemotherapy and hospice enrollment in late‐stage ovarian cancer patients

Taniguchi, Hiroshi; Ito, Y.; Kanazawa, Riichiro; Wada, Reona; Hosoda, Y.; Honda, Okuto; Takeyama, Ryu; Sakane, Riya; Wakimoto, Yu; Shibahara, Hiroaki

doi:10.1111/jog.12320

Cited by 7 publications

(6 citation statements)

References 28 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective study compared chemotherapy and supportive care in patients with platinum-resistant ovarian cancer after the first disease progression. The authors concluded that chemotherapy conferred no survival benefit over supportive care [4]. Another study also concluded that aggressive care did not result in improved survival.…”

Section: Plos Onementioning

confidence: 99%

See 1 more Smart Citation

Effect of delayed palliative chemotherapy on survival of patients with recurrent ovarian cancer

Pyeon

Han

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

For patients with recurrent ovarian cancer, the goals of chemotherapy include palliation of disease-related symptoms with minimum treatment-related side effects. However, there is currently a paucity of data regarding the initiation of palliative chemotherapy. This study aimed to compare the differences in survival rates and toxicities between patients with recurrent ovarian cancer who started palliative chemotherapy immediately versus those who received delayed chemotherapy. Through a retrospective chart review, patients who received more than three lines of chemotherapy were included. Based on the timing of thirdline chemotherapy initiation, the patients were divided into two groups: delayed (DTG) and immediate (ITG) treatment groups. The chi-square test or Fisher's exact tests, and t-test or Mann-Whitney U test were used for comparing variables, as appropriate. The Kaplan-Meier method was used for survival analysis. P-value of <0.05 was considered significant. Although there was no statistically significant difference, the total number of regimens and cycles was lower in the DTG than in the ITG. No differences in toxicities and survival rates were observed between the two groups. Overall, survival and toxicity did not differ significantly between the two groups. In a palliative care setting, our findings suggest that delaying the treatment had no adverse effect on survival. Despite the lack of evidence of a survival benefit with aggressive treatment, patients chose to continue chemotherapy. Because recurrent ovarian cancer is a complex condition, patients require sufficient explanation and time to fully understand the costs and benefits related to aggressive chemotherapy.

show abstract

Section: Plos Onementioning

confidence: 99%

“…For recurrent or refractory ovarian cancers, the goals of chemotherapy include palliation of disease-related symptoms and improvement of quality of life with minimum chemotherapy-related side effects [3]. However, limited data are available regarding the optimal timing for initiation of palliative chemotherapy [4].…”

Section: Introductionmentioning

confidence: 99%

Effect of delayed palliative chemotherapy on survival of patients with recurrent ovarian cancer

Pyeon

Han

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…As chemotherapy is typically discontinued following resistance, few patients with refractory disease are eligible for such studies, and small numbers of female patients included (49). Another limitation is that cytotoxic regimens differ between patients, doses are frequently altered and patients are not randomised.…”

Section: Clinical Papersmentioning

confidence: 99%

Repurposing itraconazole for the treatment of cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. The repurposing of drugs is becoming increasingly attractive as it avoids the lengthy process and cost implications associated with bringing a novel drug to market. Itraconazole is a broad-spectrum anti-fungal agent. An emerging body of in vivo, in vitro and clinical evidence have confirmed that it also possesses antineoplastic activities and has a synergistic action when combined with other chemotherapeutic agents. It acts via several mechanisms to prevent tumour growth, including inhibition of the Hedgehog pathway, prevention of angiogenesis, decreased endothelial cell proliferation, cell cycle arrest and induction of auto-phagocytosis. These allow itraconazole, either alone or in combination with other cytotoxic agents, to increase drug efficacy and overcome drug resistance. This study reviews the reported literature on the use of itraconazole in a variety of malignancies and highlights the recent insights into the critical pathways acted upon to prevent tumour growth.

show abstract

mentioning

confidence: 99%

“…Palliative chemotherapy can certainly prolong survival and improve quality of life for patients with cancers such as colorectal and ovarian cancers. 11,12 Patients' assessment of that bene t on an individual basis after experiencing the treatment is not known. We hypothesized that exploring the retrospective vantage point may o er assessments of the key question that patients face, namely whether taking palliative chemotherapy is worthwhile or not.…”

mentioning

confidence: 99%

Patients’ retrospective assessment of palliative chemotherapy for lung or gastrointestinal cancers

Kassirian¹,

Schreier²,

Sanatani³

2016

J Community Support Oncol

View full text Add to dashboard Cite

Benefit of palliative chemotherapy and hospice enrollment in late‐stage ovarian cancer patients

Abstract: Chemotherapy after 1st Ref can be offered and hospice enrollment during the terminal stages is encouraged for recurrent ovarian cancer patients.

Cited by 7 publications

References 28 publications

Effect of delayed palliative chemotherapy on survival of patients with recurrent ovarian cancer

Effect of delayed palliative chemotherapy on survival of patients with recurrent ovarian cancer

Repurposing itraconazole for the treatment of cancer

Patients’ retrospective assessment of palliative chemotherapy for lung or gastrointestinal cancers

Contact Info

Product

Resources

About